MD3744326T2 - Regim de dozare pentru dozele omise pentru esterii de paliperidonă injectabili care acționează pe termen lung - Google Patents

Regim de dozare pentru dozele omise pentru esterii de paliperidonă injectabili care acționează pe termen lung

Info

Publication number
MD3744326T2
MD3744326T2 MDE20210632T MDE20210632T MD3744326T2 MD 3744326 T2 MD3744326 T2 MD 3744326T2 MD E20210632 T MDE20210632 T MD E20210632T MD E20210632 T MDE20210632 T MD E20210632T MD 3744326 T2 MD3744326 T2 MD 3744326T2
Authority
MD
Moldova
Prior art keywords
long
dosing regimen
acting injectable
missed doses
injectable paliperidone
Prior art date
Application number
MDE20210632T
Other languages
English (en)
Inventor
Srihari Gopal
Paulien Gerarda Maria Ravenstijn
Alberto Russu
Mahesh Narain Samtani
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57072843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD3744326(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MD3744326T2 publication Critical patent/MD3744326T2/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Prezenta cerere de brevet furnizează o metodă pentru tratarea pacienţilor care au nevoie de tratament psihiatric, în care respectivul pacient este tratat cu formularea de 3 luni de palmitat de paliperidonă şi nu reuşeşte să ia următoarea doză programată de formulare de 3 luni de palmitat de paliperidonă.
MDE20210632T 2015-04-07 2016-03-30 Regim de dozare pentru dozele omise pentru esterii de paliperidonă injectabili care acționează pe termen lung MD3744326T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562144054P 2015-04-07 2015-04-07
US201562162596P 2015-05-15 2015-05-15

Publications (1)

Publication Number Publication Date
MD3744326T2 true MD3744326T2 (ro) 2024-05-31

Family

ID=57072843

Family Applications (2)

Application Number Title Priority Date Filing Date
MDE20210632T MD3744326T2 (ro) 2015-04-07 2016-03-30 Regim de dozare pentru dozele omise pentru esterii de paliperidonă injectabili care acționează pe termen lung
MDE20180155T MD3280416T2 (ro) 2015-04-07 2016-03-30 Schema de tratament în cazul dozelor omise pentru esterii de paliperidonă injectabili cu acţiune de lungă durată

Family Applications After (1)

Application Number Title Priority Date Filing Date
MDE20180155T MD3280416T2 (ro) 2015-04-07 2016-03-30 Schema de tratament în cazul dozelor omise pentru esterii de paliperidonă injectabili cu acţiune de lungă durată

Country Status (27)

Country Link
US (1) US10143693B2 (ro)
EP (3) EP3744326B1 (ro)
JP (3) JP6728221B2 (ro)
KR (2) KR20230162162A (ro)
AU (3) AU2016244801B2 (ro)
BR (1) BR112017021383A2 (ro)
CA (2) CA3088401A1 (ro)
CY (1) CY1123203T1 (ro)
DK (2) DK3744326T3 (ro)
EA (1) EA037185B1 (ro)
ES (2) ES2967585T3 (ro)
FI (1) FI3744326T3 (ro)
HK (1) HK1249047A1 (ro)
HR (2) HRP20240022T1 (ro)
HU (2) HUE049485T2 (ro)
IL (2) IL309340A (ro)
LT (2) LT3744326T (ro)
MA (1) MA41917B1 (ro)
MD (2) MD3744326T2 (ro)
NZ (2) NZ735952A (ro)
PL (2) PL3280416T3 (ro)
PT (2) PT3280416T (ro)
RS (2) RS65024B1 (ro)
SI (2) SI3280416T1 (ro)
TW (1) TWI694825B (ro)
UA (1) UA118732C2 (ro)
WO (1) WO2016164218A1 (ro)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3744326B1 (en) 2015-04-07 2023-12-06 Janssen Pharmaceutica NV Dosing regimen for missed doses for long-acting injectable paliperidone esters
CA3077224A1 (en) * 2017-10-27 2019-05-02 Shandong Luye Pharmaceutical Co., Ltd. Dosage regimen of paliperidone palmitate extended-release injectable suspension
KR20230116837A (ko) 2020-11-30 2023-08-04 얀센 파마슈티카 엔.브이. 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
CN116528837A (zh) * 2020-11-30 2023-08-01 詹森药业有限公司 用于确保棕榈酸帕潘立酮制剂再悬浮的方法
US11666697B2 (en) 2020-11-30 2023-06-06 Janssen Pharmaceutica Nv Methods for ensuring resuspension of paliperidone palmitate formulations
JP2023551009A (ja) 2020-11-30 2023-12-06 ヤンセン ファーマシューティカ エヌ.ベー. 持続放出パリペリドン注射可能製剤に関連する投与レジメン
HUE065573T2 (hu) 2020-11-30 2024-06-28 Janssen Pharmaceutica Nv Elnyújtott felszabadulású paliperidon injektálható készítményeihez kapcsolódó adagolási rendek
CA3229731A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
US20230085549A1 (en) * 2021-08-30 2023-03-16 Janssen Pharmaceutica Nv Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
JP5825786B2 (ja) * 2007-12-19 2015-12-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap 長時間作用型注入可能パリペリドンエステルに関連する投薬計画
WO2011042453A1 (en) * 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
MX2012005083A (es) 2009-10-30 2012-09-28 Janssen Pharmaceutica Nv Regimen de dosificacion asociado con esteres de paliperidona inyetables de accion prolongada.
ES2456917T3 (es) * 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Formulación de implante de paliperidona
EP3744326B1 (en) 2015-04-07 2023-12-06 Janssen Pharmaceutica NV Dosing regimen for missed doses for long-acting injectable paliperidone esters

Also Published As

Publication number Publication date
DK3280416T3 (da) 2020-05-11
MD3280416T2 (ro) 2020-10-31
TW201642863A (zh) 2016-12-16
JP2018510894A (ja) 2018-04-19
CA2925908A1 (en) 2016-10-07
EP3280416A4 (en) 2019-01-23
TWI694825B (zh) 2020-06-01
FI3744326T3 (fi) 2024-02-02
EA201792209A1 (ru) 2018-02-28
CY1123203T1 (el) 2021-10-29
PT3280416T (pt) 2020-06-30
AU2016244801A1 (en) 2017-10-05
IL254669B2 (en) 2024-05-01
PT3744326T (pt) 2024-01-15
DK3744326T3 (da) 2024-02-05
RS60510B1 (sr) 2020-08-31
JP2020090498A (ja) 2020-06-11
ES2802299T3 (es) 2021-01-18
SI3280416T1 (sl) 2020-07-31
KR20170134583A (ko) 2017-12-06
EP3280416B1 (en) 2020-04-22
IL254669B1 (en) 2024-01-01
EP3744326B1 (en) 2023-12-06
AU2020239611A1 (en) 2020-10-15
JP7228503B2 (ja) 2023-02-24
HUE049485T2 (hu) 2020-09-28
HRP20240022T1 (hr) 2024-03-29
IL309340A (en) 2024-02-01
EP3280416A1 (en) 2018-02-14
ES2967585T3 (es) 2024-05-03
JP7422277B2 (ja) 2024-01-26
PL3744326T3 (pl) 2024-03-25
AU2016244801B2 (en) 2020-06-25
EP4349323A3 (en) 2024-06-12
JP2021130680A (ja) 2021-09-09
AU2022221405A1 (en) 2022-09-15
HUE065435T2 (hu) 2024-05-28
EA037185B1 (ru) 2021-02-17
RS65024B1 (sr) 2024-01-31
CA3088401A1 (en) 2016-10-07
JP6728221B2 (ja) 2020-07-22
LT3744326T (lt) 2023-12-27
NZ735952A (en) 2022-02-25
BR112017021383A2 (pt) 2018-07-03
CA2925908C (en) 2020-09-01
NZ758246A (en) 2024-05-31
AU2020239611B2 (en) 2022-07-21
IL254669A0 (en) 2017-11-30
AU2022221405B2 (en) 2024-08-01
PL3280416T3 (pl) 2020-12-14
WO2016164218A1 (en) 2016-10-13
HRP20201027T1 (hr) 2020-12-11
KR20230162162A (ko) 2023-11-28
EP4349323A2 (en) 2024-04-10
KR102606678B1 (ko) 2023-11-24
UA118732C2 (uk) 2019-02-25
US20170281629A1 (en) 2017-10-05
US10143693B2 (en) 2018-12-04
MA41917B1 (fr) 2020-07-29
LT3280416T (lt) 2020-06-25
HK1249047A1 (zh) 2018-10-26
EP3744326A1 (en) 2020-12-02
SI3744326T1 (sl) 2024-02-29

Similar Documents

Publication Publication Date Title
MD3744326T2 (ro) Regim de dozare pentru dozele omise pentru esterii de paliperidonă injectabili care acționează pe termen lung
MX2021000609A (es) Métodos de tratamiento con fármacos sustrato para cyp3a4.
MX2017006312A (es) Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
CL2012001110A1 (es) Régimen de dosificación para administrar palmitato de paliperidona inyectable de depósito a un paciente que necesite tratamiento psiquiátrico que haya sido tratado con palmitato de paliperidona y que ha omitido la próxima dosis de mantenimiento programada; metodo para tratar psicosis, esquizofrenia y trastorno bipolar.
MY189333A (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
MX2016005532A (es) Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades.
EA201590058A1 (ru) Аналоги глюкагона
AR101740A1 (es) Terapia de combinación y composiciones
AR100191A1 (es) Método para tratar adenocarcinoma de pulmón
MX2022000746A (es) Dimetilfumarato y regimenes de vacunacion.
CY1122508T1 (el) Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου
NZ723139A (en) Fgf-18 compound dosing regimen
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
PH12017500617A1 (en) Dosage regimen for pegylated interferon
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
EA201791038A1 (ru) Лечение непереносимости энтерального питания
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
MA53511B1 (fr) Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée
GEP20196947B (en) Bremelanotide therapy for female sexual dysfunction
UA115887U (xx) Спосіб терапії порушень фолікулогенезу у хворих на синдром полікістозних яєчників
RU2013100450A (ru) Способ лечения желчнокаменной болезни в эксперименте
RU2012110137A (ru) Способ лечения инсулинорезистентности
UA95834U (uk) Спосіб лікування гострого ішемічного інсульту
UA91254U (uk) Спосіб лікування діабетичної ретинопатії
UA82641U (ru) Способ лечения нейросифилиса с паренхиматозными изменениями